<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001516</url>
  </required_header>
  <id_info>
    <org_study_id>LM302-01-101</org_study_id>
    <nct_id>NCT05001516</nct_id>
  </id_info>
  <brief_title>Study of LaNova Medicines(LM)-302 in Patients With Advance Solid Tumors</brief_title>
  <official_title>A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients With Claudin(CLDN)18.2-Positive Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LaNova Medicines Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LaNova Medicines Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in&#xD;
      Patients with CLDN18.2-Positive Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in&#xD;
      Patients with CLDN18.2-Positive Advanced Solid Tumors&#xD;
&#xD;
      The study schedule includes screening visit (28 days prior to accept the investigational&#xD;
      medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of&#xD;
      treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early&#xD;
      withdrawal).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">May 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Arm1:LM302 0.2 mg/kg i.v., QW×3 weeks group; Arm2:LM302 0.4 mg/kg i.v., QW×3 weeks group; Arm3:LM302 0.8 mg/kg i.v., QW×3 weeks group; Arm4:LM302 1.6 mg/kg i.v., QW×3 weeks group; Arm5:LM302 2.4 mg/kg i.v., QW×3 weeks group; Arm6:LM302 2.8 mg/kg i.v., QW×3 weeks group;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>Cycle 1 of each cohort. Duration of one cycle is 21 days</time_frame>
    <description>DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events and serious adverse events</measure>
    <time_frame>From the first administration in Cycle 1 date 1(C1D1)up to 1 year</time_frame>
    <description>The safety profile of LM302 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs-ear temperature</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Change in vital signs-ear temperature will be measured after the subject has been fully rested</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs-pulse rate</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Change in vital signs-pluse rate will be measured after the subject has been fully rested.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs-systolic pressure</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Change in vital signs-systolic pressure will be measured after the subject has been fully rested.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vital Signs-diastolic blood pressure</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Change in vital signs-diastolic blood pressure will be measured after the subject has been fully rested.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Physical examination-weight</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Change in Physical examination-weight will be measured with only light clothes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Clinical Laboratory Test Results-hematology</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Number of participants with incidence of abnormal clinical lab test results like hematology will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Clinical Laboratory Test Results-Biochemistry</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Number of participants with incidence of abnormal clinical lab test results like Biochemistry will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Clinical Laboratory Test Results-Urinalysis</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Number of participants with incidence of abnormal clinical lab test results like Urinalysis will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Abnormal Clinical Laboratory Test Results-Coagulation test</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>Number of participants with incidence of abnormal clinical lab test results like Coagulation test will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (ECG)-(R wave)RR interval</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>RR interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once. RR is the standard heart rate which calculated by 60 divided by heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (ECG)-QT interval</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>QT interval of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (ECG)-QRS duration</measure>
    <time_frame>Baseline C1D1through approximately 1 year after first administration of LM302</time_frame>
    <description>QRS duration of 12-lead ECG will be performed in the supine position after the patients are fully rested at each timepoint for once.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration versus time curve within one dosing interval (AUCtau)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Blood samples will be collected at time points of 0 h, immediately after infusion stop, as well as at 1 h,4 h, 8 h, 24 h, 48 h (Day 3), 168 h (Day 8), and 336 h (Day 15) after infusion stop in cycle 1 and cycle 4; 0 h in cycle 2, cycle 3 and cycle 5; pre-dose (0 h) will be collected in every other cycle for the subsequent cycles. i.e., in cycle 6, cycle 8, … etc.; at EOT/early withdraw from the study (if the EOT/early withdraw occur when PK blood sampling isn't stipulated). The timepoints of PK sample may be adjusted base on the human PK data. The blood samples for PK analysis will be collected as much as possible if the subjects end of treatment/early withdraw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration（Cmin）</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentration (Tmax)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (T1/2)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>To determine the pharmacokinetics (PK) profile of LM302</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate of LM-302.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: objective response rate (ORR, complete response(CR)+ partial response(PR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of LM-302.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: Duration of response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of LM-302.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator: disease control rate (DCR, CR+PR+SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of LM-302.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Preliminary anti-tumor activity of LM-302 according to RECIST v1.1 assessed by investigator:progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immunogenicity of LM-302;</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Blood samples collected for Anti-Drug Antibody(ADA) assessment will be performed at 0 h of Day 1 (within 30 min prior to infusion) in cycle 1 to Cycle 5; 0 h of Day 1 in every other cycle (within 30 min prior to infusion) for the subsequent cycles, i.e., in cycle 6, cycle 8, … etc., the EOT/early withdraw from the study and safety follow-up. Nab will be detected if necessary.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To explore the correlation between CLDN18.2 expression and anti-tumor activity of LM-302</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Test CLDN18.2 expression and anti-tumor activity of LM-302</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
first dose: 0.2mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 2, 0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
second dose: 0.4mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=3;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 3, 0.8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
third dose: 0.8mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 4, 1.6mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
fourth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=6;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 5, 2.4mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
fifth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=9;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LM302 Dose Escalation Level 6, 2.8mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation scheme using the the accelerated titration design for dose 1 and the i3+3 design for the remaining doses.&#xD;
sixth dose: 1.6mg/kg i.v. every 3 weeks (1 cycle=21 days) , n=12;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LM-302</intervention_name>
    <description>All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.</description>
    <arm_group_label>LM302 Dose Escalation Level 1, 0.2 mg/kilogram(kg),</arm_group_label>
    <arm_group_label>LM302 Dose Escalation Level 2, 0.4 mg/kg</arm_group_label>
    <arm_group_label>LM302 Dose Escalation Level 3, 0.8 mg/kg</arm_group_label>
    <arm_group_label>LM302 Dose Escalation Level 4, 1.6mg/kg</arm_group_label>
    <arm_group_label>LM302 Dose Escalation Level 5, 2.4mg/kg</arm_group_label>
    <arm_group_label>LM302 Dose Escalation Level 6, 2.8mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are fully informed of the purpose, nature, method and possible adverse&#xD;
             reactions of the study, and are willing to participate in the study and sign the&#xD;
             informed consent form (ICF) prior to any procedure;&#xD;
&#xD;
          -  Aged ≥18 years old when sign the ICF, male or female;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no&#xD;
             deterioration within 2 weeks prior to the first dose;&#xD;
&#xD;
          -  Life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Phase Ⅰa (Dose Escalation): Subjects must have histological or cytological&#xD;
             confirmation of recurrent or refractory advanced solid tumors, and have progressed on&#xD;
             standard therapy, or are intolerable for available standard therapy , or there is no&#xD;
             available standard therapy. The advanced solid tumors include but not limit to gastric&#xD;
             and gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, pancreatic&#xD;
             carcinoma, biliary tract carcinoma, colorectal carcinoma, ovarian carcinoma.&#xD;
&#xD;
          -  Claudin18.2(CLDN18.2) status will be tested by central immunohistochemistry (IHC)&#xD;
             testing for the enrolled subjects if the archived tumor tissue samples are available,&#xD;
             and the enrolment is not dependent on the CLDN18.2's status.&#xD;
&#xD;
          -  CLDN18.2 positive may be required for the high dose levels as determined by Safety&#xD;
             Monitoring Committee(SMC), the subjects need to have CLDN 18.2 positive available&#xD;
             before enrolled and dosed, and the tumor types are limited to the types listed as&#xD;
             phase Ib (Dose expansion).&#xD;
&#xD;
          -  Phase Ib (Dose Expansion): Subjects must have histological or cytological confirmation&#xD;
             of recurrent or refractory CLDN18.2 positive* advanced solid tumors, and have&#xD;
             progressed on standard therapy, or are intolerable for available standard therapy , or&#xD;
             there is no available standard therapy. The advanced solid tumors include the&#xD;
             following or the specific tumor types that are determined by SMC:&#xD;
&#xD;
          -  Gastric and gastroesophageal junction adenocarcinoma;&#xD;
&#xD;
          -  Pancreatic carcinoma;&#xD;
&#xD;
          -  Biliary tract carcinoma;&#xD;
&#xD;
          -  Colorectal carcinoma with known Microsatellite instability-high(MSI-H)/Different&#xD;
             Mismatch Repair(dMMR);&#xD;
&#xD;
          -  Esophageal adenocarcinoma;&#xD;
&#xD;
          -  Ovarian mucinous carcinoma;&#xD;
&#xD;
             *CLDN18.2-positive: defined as CLDN18.2 expression confirmed by central&#xD;
             immunohistochemistry (IHC) test and with a staining intensity of 1+ to 3+ in ≥ 10% of&#xD;
             the tumor cell. At least 3 subjects with a staining intensity of 2+ to 3+ in ≥ 40% of&#xD;
             the tumor cells should be included for the dose expansion stage.&#xD;
&#xD;
          -  At least one evaluable lesion (including measurable and unmeasurable) for phase Ia&#xD;
             dose escalation, and one measurable lesion for phase Ib dose expansion, according to&#xD;
             RECIST v1.1;&#xD;
&#xD;
          -  Subjects must show appropriate organ and marrow function in laboratory examinations&#xD;
             within 7 days prior to the first dose:&#xD;
&#xD;
          -  Bone marrow reserve: Platelet count (PLT) ≥ 90 × 109/L; Absolute neutrophil count&#xD;
             (ANC) ≥ 1.5 × 109/L; Haemoglobin ≥ 9 g/dL, without receiving Erythropoietin(EPO),&#xD;
             G-Colony-Stimulating Factor(CSF), or Granulocyte-Macrophage Colony Stimulating&#xD;
             Factor(GM-CSF) within 14 days and blood transfusion including red blood cell and&#xD;
             platelet transfusion in at least 7 days prior to first dose;&#xD;
&#xD;
          -  Coagulation function: International Normalized Ratio(INR) ≤ 1.5; Activated Partial&#xD;
             Thromboplastin Time(APTT) ≤ 1.5 × ULN;&#xD;
&#xD;
          -  Liver function: Total bilirubin ≤ 1.5 × ULN (Subjects with Gilbert's Syndrome are&#xD;
             allowed if total bilirubin ≤ 3 × ULN); Aspartate Transaminase(AST) and Alanine&#xD;
             Aminotransferase(ALT) ≤ 2.5 × ULN without liver metastases (≤ 5 × ULN if liver&#xD;
             metastases are present); Albumin ≥ 2.5 g/dL;&#xD;
&#xD;
          -  Kidney function: Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min&#xD;
             (using Cockcroft-Gault formula);&#xD;
&#xD;
          -  Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50%; QT interval (QTcF)&#xD;
             ≤ 480 ms;&#xD;
&#xD;
          -  Subjects who are able to communicate we&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to any IMP, or participate in any other clinical trial within 21 days prior&#xD;
             to 1st dosing of LM-302;&#xD;
&#xD;
          -  Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-302,&#xD;
             including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy,&#xD;
             etc. Following treatments have different time limits:&#xD;
&#xD;
          -  Local small-scale palliative radiotherapy (bone metastasis radiotherapy to control&#xD;
             pain) within 14 days prior to 1st dosing;&#xD;
&#xD;
          -  Oral anti-tumor therapy, including fluorouracil antitumor drugs and small molecular&#xD;
             targeted drugs, etc. within 14 days or 5 half-life of the drug (whichever is shorter)&#xD;
             prior to 1st dosing;&#xD;
&#xD;
          -  Traditional Chinese medicine with anti-tumor indication within 14 days prior to 1st&#xD;
             dosing.&#xD;
&#xD;
          -  Nitrosourea or Mitomycin C within 42 days prior to 1st dosing.&#xD;
&#xD;
          -  Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of&#xD;
             CTCAE v5.0 (Except for toxicities without safety risk judged by the investigator, such&#xD;
             as alopecia, and other ≤ grade 2 long term toxicities);&#xD;
&#xD;
          -  Pre-existing peripheral sensory or motor neuropathy ≥ Grade 2;&#xD;
&#xD;
          -  Subjects with uncontrolled tumor-related pain. Subjects requiring analgesic treatment&#xD;
             must be on a stable regimen before participating in the study. Symptomatic lesions&#xD;
             amenable by palliative radiotherapy (e.g., bone metastases or metastases causing nerve&#xD;
             damage) should be treated prior to enrolment. For the asymptomatic metastatic lesions&#xD;
             whose further growth would likely cause functional defects or intractable pain, if&#xD;
             appropriate, local treatment should be considered before enrolment;&#xD;
&#xD;
          -  Subjects with known central nervous system (CNS) or meningeal metastasis;&#xD;
&#xD;
          -  Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
             requiring recurrent drainage procedures;&#xD;
&#xD;
          -  Subjects who are allergic or hypersensitive to LM-302 (The excipients are L-Glutamic&#xD;
             acid, L-Arginine, Trehalose dihydrate and polysorbate 80 (for injection)) or similar&#xD;
             products;&#xD;
&#xD;
          -  Subjects who have received the treatment targeting to CLDN18.2 or Monomethyl&#xD;
             Auristatin E(MMAE) based Antibody-Drug Conjugates (ADCs):&#xD;
&#xD;
          -  Subjects who have received the treatment with ADCs targeting to CLDN18.2 are not&#xD;
             eligible;&#xD;
&#xD;
          -  Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2&#xD;
             antibodies are not eligible, but can be enrolled if they were tolerable to the&#xD;
             treatments and have experienced a 28-day's washout period prior to 1st dosing of&#xD;
             LM-302;&#xD;
&#xD;
          -  For Phase Ib (Dose Expansion), subjects who were not response to the treatment with&#xD;
             MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible;&#xD;
&#xD;
          -  Administrate strong inhibitors/strong inducers of CYP3A4 within 14 days prior to 1st&#xD;
             dosing of LM-302;&#xD;
&#xD;
          -  Subjects with known active keratitis or corneal ulcerations. Subjects with superficial&#xD;
             punctate keratitis are allowed if the disorder is being adequately treated in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Use of any live vaccines (e.g., against infectious diseases such as influenza,&#xD;
             varicella, COVID-19, etc.) within 28 days prior to 1st dosing of LM-302;&#xD;
&#xD;
          -  Subjects with the history of interstitial lung disease or drug-induced interstitial&#xD;
             lung disease/pneumonitis;&#xD;
&#xD;
          -  Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin&#xD;
             K antagonists (except for preventive treatment at a stable dose);&#xD;
&#xD;
          -  Subjects with gastric outlet obstruction, persistent recurrent vomiting or&#xD;
             uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st&#xD;
             dosing of LM-302;&#xD;
&#xD;
          -  Subjects who received major surgery or interventional treatment within 28 days prior&#xD;
             to 1st dosing of LM-302 (excluding tumor biopsy, puncture, etc.);&#xD;
&#xD;
          -  Subjects who have other active malignancies which are likely to require the treatment;&#xD;
&#xD;
          -  Subjects who have severe cardiovascular disease, including but not limited to:&#xD;
&#xD;
          -  Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia&#xD;
             requiring clinical intervention, and II-III degree atrioventricular block, etc.;&#xD;
&#xD;
          -  Thromboembolic events requiring therapeutic anticoagulation, or equipped with venous&#xD;
             filters;&#xD;
&#xD;
          -  Cardiac insufficiency of grade III~IV according to the New York Heart Association&#xD;
             (NYHA) standards;&#xD;
&#xD;
          -  Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other&#xD;
             cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months&#xD;
             prior to 1st dosing of LM-302;&#xD;
&#xD;
          -  Clinically uncontrollable hypertension;&#xD;
&#xD;
          -  Subjects who have uncontrolled or severe illness, including but not limited to ongoing&#xD;
             or active infection (e.g., active Corona Virus Disease 2019（COVID-19）/Severe Acute&#xD;
             Respiratory Syndromes(SARS)-COVID-2 infection, etc.) requiring antibiotics and/or&#xD;
             other therapeutic administration, while SARS-COVID-2 testing is not mandatory for&#xD;
             study entry, and the testing should follow local clinical practice&#xD;
             guidelines/standards.&#xD;
&#xD;
          -  Subjects who have a history of immunodeficiency disease, including other acquired or&#xD;
             congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone&#xD;
             marrow transplantation, or autologous hematopoietic stem cell transplantation;&#xD;
&#xD;
          -  HIV infection, active Hepatitis B Virus(HBV) and Hepatitis C Virus(HCV)infection, with&#xD;
             the exception:&#xD;
&#xD;
          -  Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B&#xD;
             core antibody [anti-hepatitis B core(HBc)] and absence of HBsAg), as well as with&#xD;
             normal liver function are eligible. Otherwise, if HBV infection was indicated, those&#xD;
             with HBV DNA &lt; 500 IU/ML (or equivalent level) and normal liver function, combined&#xD;
             with clinical manifestations, judged by the investigator to exclude active infection&#xD;
             can be enrolled;&#xD;
&#xD;
          -  Subjects with positive HCV antibody but negative hepatitis C virus RNA test results&#xD;
             and normal liver function are eligible.&#xD;
&#xD;
          -  Child-bearing potential female who have positive results in pregnancy test or are&#xD;
             lactating;&#xD;
&#xD;
          -  Subjects who have psychiatric illness or disorders that may preclude study compliance;&#xD;
&#xD;
          -  Subject who is judged as not eligible to participate in this study by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Skeel Roland</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Toledo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajita Narayan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Horizon Oncology Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Chao</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope National Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaffer Ajani</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas MD Anderson</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Kurkjian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Clinic Oncology and Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Zhu</last_name>
    <phone>13917933915</phone>
    <email>JaneZhu@lanovamed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Huang</last_name>
    <phone>13764134848</phone>
    <email>ellenhuang@lanovamed.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

